Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMX-30063 versus daptomycin for initial treatment of Staphylococcus aureus ABSSSI
2011-003741-17Phase 2Terminated
- Sponsor
- PolyMedix, Inc.
- Start
- Jan 2012
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of brilacidin in acute bacterial skin and skin structure infection (ABSSSI) and Staphylococcus aureus skin infection (2 arms), sponsored by PolyMedix, Inc. Primary endpoint: Bacteriologic eradication at end of treatment. Started Jan 2012; status: terminated.
02
Drugs
brilacidin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)Staphylococcus aureus skin infection
Beyond the preview
Go deeper on 2011-003741-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003741-17.